Expert-level AI applied to biology/medicine will yield cures for cancer and Alzheimer's within 5-10 years, compressing a century of progress into a decade.

Expert-level AI applied to biology/medicine will yield cures for cancer and Alzheimer's within 5-10 years, compressing a century of progress into a decade. | Phase III trials for AI-designed therapeutics

Key catalyst: Phase III trials for AI-designed therapeutics

Watch events: Alzheimer disease-modifying drug approvals; oncology complete-response rates; AI-designed clinical candidate count.

AlphaFold, Isomorphic Labs, and AI-designed biologics pipelines accelerating; GLP-1 class showed what rapid bio-progress looks like.

Beneficiaries (20)

{
  "nia": false,
  "qty": "cancer/Alzheimer cures",
  "mode": "FORECAST",
  "role": "Cited-CEO",
  "caveats": "Clinical-trial timelines and regulatory approval remain rate-limiting even with AI-accelerated discovery.",
  "context": "Amodei's 'decade of biological progress' thesis; implies Alzheimer/cancer breakthroughs in 2031-2036 window.",
  "to_year": 2036,
  "conv_cues": "will; CEO; specific diseases",
  "direction": "HAPPEN",
  "from_year": 2031,
  "timeframe": "5-10 years",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "llm_pre_event",
      "label": "Anthropic publishes follow-up to 'Machines of Loving Grace' or specific biotech roadmap update",
      "source": "https://techcrunch.com/2024/10/11/anthropic-ceo-goes-full-techno-optimist-in-15000-word-paean-to-ai/",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -9,
      "source_id": null,
      "confidence": 0.7,
      "expected_date": "2028-02-15",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2029-12-31",
        "from": "2026-04-01"
      },
      "measurement_criterion": "Amodei or Anthropic publishes essay, paper, or roadmap reaffirming or materially revising 5-10 year compressed-century thesis with measurable progress markers"
    },
    {
      "kind": "llm_pre_event",
      "label": "First AI-designed therapeutic enters Phase 3 trial for cancer or Alzheimer's",
      "source": "https://intuitionlabs.ai/articles/dario-amodei-demis-hassabis-jensen-huang-compressing-a-century-of-biology-into-a-decade",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -8,
      "source_id": null,
      "confidence": 0.6,
      "expected_date": "2028-05-01",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2029-12-31",
        "from": "2026-09-01"
      },
      "measurement_criterion": "ClinicalTrials.gov registration of Phase 3 trial where AI (Isomorphic Labs, Recursion, Insilico, BenevolentAI) is credited as primary discovery/design tool for cancer or Alzheimer's indication"
    },
    {
      "kind": "llm_pre_event",
      "label": "AlphaFold-class biology breakthrough beyond protein folding (e.g., full cellular simulation, virtual cell)",
      "source": "https://www.scientificamerican.com/article/one-of-the-biggest-problems-in-biology-has-finally-been-solved/",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -7,
      "source_id": null,
      "confidence": 0.5,
      "expected_date": "2028-09-15",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2030-12-31",
        "from": "2026-06-01"
      },
      "measurement_criterion": "Peer-reviewed Nature/Science publication of AI-driven full-cell or whole-organ simulation system at near-AlphaFold accuracy/utility"
    },
    {
      "kind": "llm_pre_event",
      "label": "FDA approval of any AI-discovered/designed cancer therapeutic",
      "source": "https://www.darioamodei.com/essay/machines-of-loving-grace",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -6,
      "source_id": null,
      "confidence": 0.55,
      "expected_date": "2029-07-01",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2031-12-31",
        "from": "2027-01-01"
      },
      "measurement_criterion": "FDA approval letter or press release for therapeutic where AI is credited as critical to discovery or design pathway, with cancer indication"
    },
    {
      "kind": "llm_pre_event",
      "label": "First disease-modifying Alzheimer's therapeutic with AI-designed mechanism enters Phase 2",
      "source": "https://www.rapamycin.news/t/dario-amodei-near-term-predictions-on-ai-advancing-science/16844",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -5,
      "source_id": null,
      "confidence": 0.45,
      "expected_date": "2029-07-01",
      "research_origin": "training",
      "expected_date_range": {
        "to": "20
... (truncated)